Table 1 Summary of demographic and laboratory variables of patients with MC disease with at least one analyzed CD marker.

From: Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

 

Cutaneous mastocytosis (CM)

Indolent systemic mastocytosis (ISM)

Smoldering systemic mastocytosis (SSM)

Advanced systemic mastocytosis (advSM)

N (% of all patients within MC disease entity)

256 (28.4)

2008 (79.6)

65 (77.3)

458 (77.6)

Median age (years) (IQR)

38 (29, 51.25)

47 (37, 57)

56 (50, 63)

64 (53, 71)

Male sex (% of N)

79 (30.9)

893 (44.5)

25 (38.5)

284 (62.0)

CD2 available (% of N)

227 (88.7)

1622 (80.8)

49 (75.4)

326 (71.2)

CD25 available (% of N)

249 (97.3)

1957 (97.5)

59 (90.8)

438 (95.6)

CD30 available (% of N)

49 (19.1)

428 (21.3)

18 (27.7)

99 (21.6)

  1. Patients with ISM were younger compared to patients with advSM, with a preponderance of male sex in the latter. In patients with SM CD25 expression was available in more than 90%, followed by CD2 expression in more than 70% and by CD30 expression in more than 20%.
  2. MC mast cells, IQR interquartile range, SM systemic mastocytosis.
Back to article page